|

Tepotinib Clinical Trials

6 actively recruiting trials across 1 location

Also known as: EMD 1214063, EMD-1214063, EMD1214063, MSC 2156119, MSC 2156119J, MSC-2156119, MSC-2156119J, MSC2156119, MSC2156119J, Tepmetko, c-Met Inhibitor MSC2156119J

Other5 trials

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Phase 2
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
Phase 1
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Phase 3
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Daphne, Alabama1 trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.